Clinical Study Explores mRNA-Based Technology for Vaccines
On July 25, 2017, the British journal The Lancet published results of an early-stage trial that could herald the arrival of a whole new class of vaccines. CureVac, a German biopharmaceutical company that focuses on therapeutic applications using messenger RNA (mRNA), announced “proof of concept” results from their Phase I study…
The Epidemic of Silence with Adverse Drug Reactions
One of the more bothersome feedback loops that keeps adverse drug reactions from being recognized is that patients stay silent about their pain and suffering, and therefore their pain and suffering is not recognized or appreciated, and everyone gets to continue to think that dangerous drugs are safe and that adverse reactions are rare.
GlaxoSmithKline Ranked Top Vaccine Maker
GlaxoSmithKline (GSK), Merck & Co., Pfizer, and Sanofi account for 80 percent of global vaccine revenues. Although these “big four” vary significantly by portfolio and pipeline size, GSK of the United Kingdom ranked first in terms of research and development, pricing strategy and registration, and manufacturing and supply, according to a report released by the Access to…
Needle-Free Vaccines Backed by Gates Foundation
The Bill & Melinda Gates Foundation recently awarded two grants worth a total of $6 million to the Boston-based life sciences company Vaxess Technologies, Inc. The grants will support research to create two micro-needle vaccine “patches” that simplify delivery of the inactivated polio (IPV) and live attenuated measles rubella (M-R) vaccines through needle-free delivery systems and […]
Hepatitis B Vaccine Global Market to Grow Over Next Decade
Hepatitis B is an infectious disease of the liver caused by the Hepatitis B virus (HBV). The symptoms of the disease do not develop until after a few weeks of exposure. Hepatitis B is usually transmitted from an infected person blood, semen and other body fluids. Hepatitis B is primarily an adult disease passed from person to person…
Pfizer, Merck, Sanofi, GSK Will Continue to Dominate the Vaccine Market
The monopoly that Pfizer Inc., Merck & Co. Inc., Sanofi and GlaxoSmithKline plc (GSK) have on the vaccine market is unlikely to be broken, according to Jeffrey Holford, an equity analyst at global investment banking firm Jefferies. That market is projected to grow from $28.3 billion in 2015 to $72.5 billion in 2024. The four companies…